ESMO 2017

REVIEW UroToday

Viewing 1-20 of 80 articles

ESMO 2017: Second-line treatment patterns and outcomes of metastatic bladder cancer patients in clinical practice

ESMO 2017: Outcomes of patients with metastatic urothelial carcinoma with exclusive bone metastases: Focus on a special patient population

ESMO 2017: Identification of genomic features underlying response of muscle-invasive bladder cancer to neoadjuvant sorafenib, gemcitabine, and cisplatin in an open-label, single-arm, phase 2 study

ESMO 2017: Kidney Cancer Poster Discussion – Invited Discussant

ESMO 2017: Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: A joint study of the EAU-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration

ESMO 2017: Avelumab treatment of metastatic urothelial carcinoma in the phase 1b JAVELIN Solid Tumor study: Updated analysis with ≥6 months of follow-up in all patients

ESMO 2017: Immunotherapy for Urothelial Cancer – Longer Follow-up and Subgroup Analyses: Invited Discussant

ESMO 2017: 14 years of progress in mCRPC – New avenues for immunotherapy and precision medicine: Invited Discussant

ESMO 2017: Prostate Cancer Poster Discussion: Invited Discussant

ESMO 2017: Urothelial Carcinoma Poster Discussion – Invited Discussant

ESMO 2017: Biological assessment of viable germ cell tumor in patients with seminoma and non-seminoma using miR371

ESMO 2017: Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma: Real world data from an Italian Expanded Access Program

ESMO 2017: SPAZO2 (SOGUG): Validation of the International Metastatic Database Consortium prognostic classification for targeted therapies as 2nd-line after 1st-line pazopanib in metastatic renal cell carcinoma

ESMO 2017: Initial Results from AQUARiUS, a Prospective, Observational, Multi-Centre Phase IV Study Assessing Patient-Reported Outcomes in mCRPC Patients Treated with Abiraterone Acetate plus prednisone or Enzalutamide

ESMO 2017: Cabazitaxel followed by ADT improves time to progression in patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A Randomized, Open Label, Phase III, Multicenter trial

ESMO 2017: Assessment of health-related quality of life in PROSELICA: A Phase 3 trial assessing cabazitaxel 20 mg/m2 vs 25 mg/m2 in post-docetaxel patients with metastatic castration-resistant prostate cancer (mCRPC)

ESMO 2017: Outcomes of patients with metastatic renal cell carcinoma who were treated with second-line vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line immune checkpoint inhibitor therapy

ESMO 2017: Association between biopsychosocial distress and overall survival in patients with metastatic renal cell carcinoma

ESMO 2017: SPAZO2 (SOGUG): Comparative effectiveness of everolimus vs axitinib as second-line after first-line pazopanib in metastatic renal carcinoma

ESMO 2017: Do patients with advanced nonseminomatous germ cell tumors and unfavorable time to normalization of tumor markers benefit with prolongation of 1-st line chemotherapy?

1
2
3
4